Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Newly Developed Compound Protects Heart Cells During and After Infarction

By BiotechDaily International staff writers
Posted on 18 Feb 2013
Print article
Using two recently developed diverse compounds, scientists have been able to show in animal models that suppressing a specific enzyme protects heart cells and neighboring tissue against the debilitating injury incurred by heart attacks. The compounds also protect against additional damage from restored blood flow after an attack, a process known as reperfusion.

The study, which was led by Dr. Philip LoGrasso, a professor and senior scientific director of discovery biology at the Florida campus of The Scripps Research Institute (TSRI; Jupiter, USA), was published in the February 8, 2013, print edition of the Journal of Biological Chemistry.

A myocardial infarction greatly restricts blood supply, starving heart cells and neighboring tissue of oxygen, which can cause enormous damage in comparatively little time—at times in just a few minutes. This decrease in oxygen, known as an ischemic cascade, results in a sudden crush of metabolic waste that damages cell membranes as well as the mitochondria.

Restoring blood flow adds considerably to the damage, unfortunately, a serious medical issue when it comes to treating major ischemic events such as stroke and heart attack. Reperfusion triggers generation of free radicals and reactive oxygen species that attack and damage cells, intensifying inflammation, signaling white blood cells to attack otherwise salvageable cells and maybe even stimulating potentially lethal cardiac arrhythmias.

The new study revealed that inhibiting the enzyme, c-jun-N-terminal kinase (JNK; pronounced junk), protected against ischemic/reperfusion injury in lab rodents, reducing the total volume of tissue death by as much as 34%. It also substantially decreased levels of reactive oxygen species and mitochondrial dysfunction.

In earlier studies, TSRI scientists discovered that JNK migrates to the mitochondria upon oxidative stress. That migration, combined with JNK activation, they found, is associated with a number of severe health issues, including liver damage, neuronal cell death, stroke, and heart attack. The peptide and small molecule inhibitor (SR3306), developed by Dr. LoGrasso and his colleagues, blocks those harmful effects, thereby reducing programmed cell death four-fold.

“This is the same story,” said Dr. LoGrasso. “These just happen to be heart cells, but we know that oxidative stress kills cells, and JNK inhibition protects against this stress. Blocking the translocation of JNK to the mitochondria is essential for stopping this killing cascade and may be an effective treatment for damage done to heart cells during an ischemic/reperfusion event.”

Moreover, according to Dr. LoGrasso, biomarkers that intensify during a heart attack decrease in the presence of JNK inhibition, a distinct indication that blocking JNK reduces the severity of the infarction.

Related Links:

The Scripps Research Institute




Print article

Channels

Genomics/Proteomics

view channel
Image: The first 3D map of the cancer-associated protein DCLK1 (doublecortin-like kinase 1), revealed how it functions (Photo courtesy of Walter and Eliza Hall Institute).

Kinase Domain Mutation Causes Protein Malfunction and Tumor Development

A team of chemical biologists has generated the first molecular map of the protein doublecortin kinase like domain 1 (DCLK1), a factor linked to more than 10% of gastric cancers that has also been found... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.